Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results
MEDIA COVERAGE
Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS
Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic hematopoietic cell transplantation (alloHCT) and subsequently relapsed.
Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas
Researchers from Baylor College of Medicine and Texas Children’s Hospital are exploring “non-engineered” T-cell therapies that are easier to manufacture and able to target multiple antigens.
Houston: One of the Fastest-Growing Life Science Communities
A recent report by CBRE Research analyzing U.S. life science clusters found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017.
Marker Therapeutics Rockets After CEO Says Phase 2 Leukemia Trial with T-cell Therapy in Works
With the help of Marker’s technology, a population of T-cells attacks multiple cancer targets and works to activate a patient’s immune system to trigger anti-tumor activity.
Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street
DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.
QUOTES
“I believe that the new therapies we are acquiring with Marker in this transaction represent the next major leap forward in cell therapy for cancer. The merger adds to our product pipeline a synergistic portfolio of highly-differentiated T cell therapies that has demonstrated potentially groundbreaking results in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.”
Peter L. Hoang, President & CEO
“With this merger, I believe we have the opportunity to significantly disrupt the CAR-T and TCR field. Compared to current gene-modified T cell therapies such as CAR-T and TCR, the therapies we are acquiring in this transaction are highly efficacious and extremely durable, without the need for lymphodepletion before infusion, non gene-modified, significantly less toxic than CAR-T, multi-antigen specific, capable of driving an endogenous immune response, and capable of addressing patients currently inaccessible to CAR-T therapies.”
Peter L. Hoang, President & CEO
LOGO USAGE
COLORS
Primary Color
#233E7B
Secondary Color
#3D759B
Dark Color
#161819
TEAM PHOTOS
